TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
12 janv. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
11 janv. 2024 08h00 HE
|
TransCode Therapeutics, Inc.
TransCode Announces Reverse Stock Split
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
04 janv. 2024 08h05 HE
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders of TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
12 déc. 2023 08h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
05 déc. 2023 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present...
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
04 déc. 2023 16h10 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
30 nov. 2023 14h53 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
14 nov. 2023 16h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Withdraws Public Offering
30 oct. 2023 16h33 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
27 oct. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...